# Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

> **NCT03239860** · PHASE2 · TERMINATED · sponsor: **GeNeuro SA** · enrollment: 220 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** GNbAC1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT03239860
- **Lead sponsor:** GeNeuro SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-06
- **Primary completion:** 2018-11-14
- **Final completion:** 2018-11-14
- **Target enrollment:** 220 (ACTUAL)
- **Why stopped:** Based on R\&D strategic reasons, our co-development Partner financing the study disengaged from the development of GNbAC1.
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239860, "Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03239860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*